A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Trial Profile

A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Ibrutinib (Primary) ; Temsirolimus
  • Indications Mantle-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms NAP; RAY
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results comparing the effectiveness of Ibrutinib in this study versus the Real-World Treatments in Mantle Cell Lymphoma patients, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Dec 2017 According to a Janssen Research & Development media release, results of pooled analysis from SPARK, PCYC-1104, RAY and CAN3001 studies (n=370) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top